Preserving the Liver for Second-Line Treatment of Hepatocellular Carcinoma

被引：0
|
作者：
Lencioni, Riccardo [1 ,2 ]
机构：
[1] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Dept Intervent Radiol,Intervent Radiol, Miami, FL 33136 USA
[2] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Dept Intervent Radiol,Clin & Translat Res, Miami, FL 33136 USA
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2016年 / 14卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6 / 8
页数：3
相关论文
共 50 条
  • [41] Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment
    Sadahisa Ogasawara
    Tetsuhiro Chiba
    Yoshihiko Ooka
    Eiichiro Suzuki
    Takahiro Maeda
    Masayuki Yokoyama
    Toru Wakamatsu
    Masanori Inoue
    Tomoko Saito
    Kazufumi Kobayashi
    Soichiro Kiyono
    Masato Nakamura
    Shingo Nakamoto
    Shin Yasui
    Akinobu Tawada
    Makoto Arai
    Tatsuo Kanda
    Hitoshi Maruyama
    Osamu Yokosuka
    Naoya Kato
    Investigational New Drugs, 2018, 36 : 332 - 339
  • [42] Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib
    Olivier Mir
    Romain Coriat
    Pascaline Boudou-Rouquette
    Stanislas Ropert
    Jean-Philippe Durand
    Anatole Cessot
    Vincent Mallet
    Philippe Sogni
    Stanislas Chaussade
    Stanislas Pol
    François Goldwasser
    Medical Oncology, 2012, 29 : 2793 - 2799
  • [43] Sorafenib as second-line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma
    Tomonari, Tetsu
    Sato, Yasushi
    Tanaka, Hironori
    Tanaka, Takahiro
    Taniguchi, Tatsuya
    Sogabe, Msasahiro
    Okamoto, Koichi
    Miyamoto, Hiroshi
    Muguruma, Naoki
    Takayama, Tetsuji
    JGH OPEN, 2020, 4 (06): : 1135 - 1139
  • [44] Second-line Treatment Strategy in Unresectable Hepatocellular Carcinoma After First-line Atezolizumab Plus Bevacizumab
    Mohri, Kunihide
    Nagai, Hidenari
    Matsuda, Takahisa
    Igarashi, Yoshinori
    Higai, Koji
    ANTICANCER RESEARCH, 2024, 44 (09) : 3919 - 3929
  • [45] Feasibility, safety, and outcome of second-line nivolumab/bevacizumab in liver transplant patients with recurrent hepatocellular carcinoma
    Di Marco, Lorenza
    Pivetti, Alessandra
    Foschi, Francesco Giuseppe
    D'Amico, Roberto
    Schepis, Filippo
    Caporali, Cristian
    Casari, Federico
    Lasagni, Simone
    Critelli, Rosina Maria
    Milosa, Fabiola
    Romanzi, Adriana
    Marcelli, Gemma
    De Maria, Nicola
    Romagnoli, Dante
    Catellani, Barbara
    Sciano, Filippo
    Magistri, Paolo
    Colecchia, Antonio
    Sighinolfi, Pamela
    Di Benedetto, Fabrizio
    Martinez-Chantar, Maria-Luz
    Villa, Erica
    LIVER TRANSPLANTATION, 2023, 29 (05) : 559 - 563
  • [46] Platinum rechallenge in second-line treatment for endometrial carcinoma
    Pereira Souza, R.
    Pinheiro Soares, G.
    Valente Lage, L.
    Baiocchi, G.
    da Costa, A. A. B. A.
    Eestevez Diz, M. del Pilar
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2019, 40 (06) : 963 - 969
  • [47] Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma
    Chiang, Chi-leung
    Chan, Sik-kwan
    Lee, Shing-fung
    Wong, Irene Oi-ling
    Choi, Horace Cheuk-wai
    JAMA NETWORK OPEN, 2021, 4 (01)
  • [48] Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The Evidence
    De Luca, Emmanuele
    Marino, Donatella
    Di Maio, Massimo
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 3721 - 3729
  • [49] Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Prognosis, efficacy, and safety by liver disease etiology
    Okusaka, T.
    Blanc, J-F.
    Chau, I.
    Yang, L.
    Abada, P.
    Zhu, A. X.
    ANNALS OF ONCOLOGY, 2016, 27
  • [50] Efficacy and safety of regorafenib as second-line treatment for patients with hepatocellular carcinoma and macrovascular invasion and(or) extrahepatic metastasis
    Zhao, Yan
    Liu, Weiling
    Zheng, Lu
    Goyal, Sharad
    Awosika, Joy
    Wang, Hailing
    Yang, Shujun
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 14 (06) : 2536 - 2548
12345